Delivers up-to-date industry news on topics like drug approvals, product recalls, company expansions and acquisitions, market trends for all OSD forms, as well as excipients, packaging and supply chain issues. Monitors market trends in specific drug categories as well as in supplements/nutraceuticals. Provides updates on clinical trials. Includes alerts about new or upcoming regulatory issues.
The global gastrointestinal drugs market is expected to grow from $71.85B in 2021 to $75.63B in 2022 at a compound annual growth rate (CAGR) of 5.3%. The change in growth trend is mainly due to the companies stabilizing their output after catering to the demand that grew exponentially during the COVID-19 pandemic in 2020. The market is expected to ...
read more
The global gynecological cancer drugs industry generated $11.6B in 2020, and is estimated to reach $21.8B by 2030, witnessing a CAGR of 6.5% from 2021 to 2030, according to a new report from Allied Market Research.
read more
Calliditas Therapeutics AB announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the granting of a conditional marketing authorisation for Kinpeygo for the treatment of primary immunoglobulin A (IgA) nephropathy (IgAN) in adults at risk of rapid ...
read more
MG America, the U.S. subsidiary of MG2 of Bologna, Italy and a leading supplier of processing and packaging equipment, has named Claudio Radossi as its next president, effective July 1. Radossi succeeds company co-founder Fabio Trippodo, who is retiring after a 35-year tenure as MG America’s president.
read more
Eli Lilly and Company announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for OLUMIANT® (baricitinib) for the treatment of adults with severe alopecia areata (AA).
read more
Tenax Therapeutics, Inc., a pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases, announced the successful completion of its comparative pharmacokinetic study of TNX-201, for the treatment of pulmonary arterial hypertension (“PAH”).
read more
EpiEndo Pharmaceuticals (‘EpiEndo’), the clinical-stage biopharmaceutical company developing disease-modifying therapeutics for chronic respiratory disorders, has completed its Phase I First Time in Human (FTIH) study with EP395 in healthy subjects.
read more
The global antifungal drugs market size is expected to reach $20.5 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 3.7% from 2022 to 2030.
read more
Polaris Market Research’s report, "Pharmaceutical Packaging Market Share, Size, Trends, Industry Analysis Report, By Material (Plastics & Polymers, Paper & Paperboard, Glass, Aluminum Foil, Others); By Product (Primary, Secondary, Tertiary); By End Use; By Region; Segment Forecast, 2022 - 2030" estimates the global pharmaceutical packaging market ...
read more
Servier announced that the U.S. Food and Drug Administration (FDA) approved TIBSOVO® (ivosidenib tablets) in combination with azacitidine for the treatment of patients with newly diagnosed IDH1-mutated acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.
read more
Perrigo Company, a provider of Consumer Self-Care Products, announced that it has received final approval from the U.S. Food and Drug Administration for Omeprazole Magnesium Delayed-Release Mini Capsules, 20 mg over-the-counter (OTC). Perrigo expects to launch Omeprazole Minis later this year.
read more
Dr. Reddy’s Laboratories Ltd. and Senores Pharmaceuticals, Inc. today announced the launch of Ketorolac Tromethamine Tablets USP, 10 mg, a therapeutic generic equivalent of the reference listed drug Toradol Tablets, 10 mg in the U.S. market approved by the U.S. Food and Drug Administration (USFDA).
read more
AbbVie announced results from three Phase 3 clinical trials – U-ACHIEVE (induction), U-ACCOMPLISH and U-ACHIEVE (maintenance) – evaluating upadacitinib (RINVOQ®) in patients with moderately to severely active ulcerative colitis who have had inadequate response, lost response or were intolerant to conventional or biologic therapy.
read more
Mezzion Pharma met with the FDA Division of Cardiology and Nephrology (DCN) May 27 to discuss with the FDA the path forward for the regulatory approval of udenafil for the treatment of single ventricle heart disease (SVHD) in children with Fontan physiology.
read more
The Global Pharmaceutical Manufacturing Market size was estimated at $454.02B in 2021, $509.45B in 2022, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 12.38% to reach $914.90By 202, according to a Research & Markets report.
read more